Individual Investors

Website_Article_Tiles_top5_US_4b892a5d9a.png
With interest rates hikes causing global share prices to tumble, investors are searching for other options. One potential option is low volatility companies, which are companies with share prices that move up and down less than average. And indeed, low volatility indexes have outperformed the past six months in the United States, where interest rates have started to climb. Below we look at the top 5 US low volatility stocks. They each feature in the ETFS S&P 500 High Yield Low Volatility ETF (ASX Code: ZYUS). Lockheed Martin (NYSE:LMT) Lockheed is perhaps the most famous name in US defence. Lockheed makes fighter jets like the F-35 and the F-21, as well as an array of missile and defence systems. As may be expected of a defence company, almost all of Lockheed’s revenue comes from selling things to governemnts. Half of its revenue comes from the US Department of Defense alone. As Lockheed’s client base is governments, and defence-related, it tends to be shielded to a large extent from economic cycles. Lockheed has also been a beneficiary of Russian aggression in Ukraine, as governments worldwide increase defence spending. ...
5_biotech_companies_you_should_know_about_-_article_thumbnail_1a4f5f652a.png
Biotechnology came into the spotlight in 2020 as many companies raced to test and register vaccines for COVID-19, however, the potential and growth of this industry extends far beyond the pandemic. Biotechnology is transforming the way we treat and manage a range of health concerns and diseases and can be a highly lucrative space. What is biotechnology? Biotechnology specifically refers to technologies that use biological processes, capturing companies that focus on research, development, manufacturing and/or marketing of products based on biological and genetic information. The different types of biotechnology include biological drugs, vaccines, immunotherapy, gene therapy, orphan drugs and genetic engineering. While Australian companies like CSL Ltd (ASX: CSL) are no slouches when it comes to innovative biotech, the US is typically viewed as the global centre. The dominance of the US market is partly due to the world-renowned US Food and Drug Administration (FDA) approval process and to the size of its customer base. As a result, many companies base themselves in the US for easier access to the process and more efficient ability to distribute and market to US consumers. Global innovators ...